Metabolic Health & Pancreatic Cancer
Pancreatic cancer has important connections to metabolism, particularly blood glucose, insulin, diabetes, and obesity.
Researchers are also investigating whether changing the body's metabolism could make conventional cancer treatments more effective.
Diabetes, Insulin Resistance & Cancer Risk
Type 2 diabetes and obesity are associated with an increased risk of pancreatic cancer.
High insulin levels, chronic inflammation, and changes in cellular metabolism may help explain these relationships.
However, the connection between diabetes and pancreatic cancer is complicated.
Long-standing diabetes may increase cancer risk, while pancreatic cancer itself can sometimes cause new-onset diabetes.
This is especially relevant when diabetes develops unexpectedly after age 50, particularly with unexplained weight loss.
Can Improving Metabolic Health Reduce Risk?
Maintaining a healthy weight, exercising regularly, avoiding smoking, and managing diabetes may help reduce pancreatic cancer risk.
Low-carbohydrate diets can improve blood glucose and insulin resistance in some people.
However, research has not established that following a low-carbohydrate diet specifically prevents pancreatic cancer.
The Metabolic Theory of Cancer
Cancer cells often use glucose differently from normal cells, a phenomenon known as the Warburg effect.
Some researchers believe these metabolic differences could be exploited to improve cancer treatment.
This has led to interest in ketogenic diets, which substantially reduce carbohydrate intake and increase the production of ketones.
However, pancreatic cancer cells can use several energy sources. Simply reducing dietary carbohydrates does not eliminate their glucose supply or starve a tumor.
Thomas Seyfried's Perspective
Dr. Thomas Seyfried, a researcher at Boston College, has been a leading advocate of the metabolic theory of cancer.
He argues that impaired cellular energy production plays a central role in cancer development and that restricting glucose and glutamine availability may help control tumor growth.
Seyfried's work challenges the conventional view that cancer is primarily driven by genetic mutations. His research has generated growing interest in metabolic approaches to cancer treatment, although larger clinical trials are still needed to determine how effective these approaches may be for pancreatic cancer.
Videos & Resources — Thomas Seyfried
A YouTube channel exploring Seyfried's research and metabolic approaches to cancer treatment.
A brief introduction to Seyfried's theory that cancer is fundamentally a disease of cellular energy metabolism.
An interview with Ralph Moss, Ph.D., discussing the metabolic theory of cancer and experimental approaches involving glucose, glutamine, and repurposed antiparasitic drugs.
An Interesting 2026 Clinical Trial
A randomized Phase II study published in March 2026 examined a medically supervised ketogenic diet combined with chemotherapy in patients with metastatic pancreatic cancer.
Among 32 evaluable patients:
Median progression-free survival: 8.5 months with the ketogenic diet versus 6.2 months with the usual diet.
Median overall survival: 13.7 months versus 10.2 months.
These findings favored the ketogenic diet, but the study was too small to establish a reliable survival benefit.
The researchers concluded that larger trials are needed.
This is encouraging preliminary evidence, not proof that ketogenic diets improve pancreatic cancer survival.
Other Metabolic Approaches
Researchers are also investigating whether drugs that affect glucose metabolism, insulin signaling, or other metabolic pathways might improve treatment.
Metformin, commonly prescribed for type 2 diabetes, has attracted interest because of its effects on cellular metabolism.
However, clinical research has not established metformin as an effective pancreatic cancer treatment.
Other experimental metabolic therapies also require stronger clinical evidence.
Nutrition Is Especially Important
Pancreatic cancer frequently causes weight loss, poor appetite, and difficulty digesting food.
Some patients develop cachexia, a serious condition involving loss of muscle and body weight.
For these patients, maintaining adequate calories, protein, and muscle mass is a major priority.
Pancreatic enzyme replacement may also be needed to improve digestion.
Restrictive diets should not be started during pancreatic cancer treatment without guidance from the oncology team and an experienced dietitian.
The Important Point
Metabolic health is clearly connected to pancreatic cancer risk, and metabolic therapies are an active area of research.
The 2026 ketogenic diet trial provides an interesting reason for further investigation.
However, metabolic therapies remain experimental for pancreatic cancer and should not replace established treatments.
For patients already diagnosed with pancreatic cancer, preserving nutrition, muscle strength, and quality of life is especially important.
Learn More
A randomized Phase II trial examining ketogenic diets alongside chemotherapy.
Experimental research in animal models investigating metabolic changes and pancreatic cancer development.
Explores the theory that cancer is primarily a metabolic disease involving impaired mitochondrial function. His research investigates ketogenic diets and strategies targeting glucose and glutamine as potential cancer therapies. Much of this work remains experimental.